|
PHILADELPHIA (AP) - GlaxoSmithKline PLC plans to launch five major vaccines over the next five years worth up to $18 billion, but still has no U.S. regulatory filing timeline for its much-touted cervical cancer vaccine, the company said Thursday.
The world's second-largest pharmaceutical company, which has its U.S. headquarters in Philadelphia and Research Triangle Park, N.C., expects by 2010 to introduce the cervical cancer vaccine, Cervarix; Rotarix, for rotavirus gastroenteritis; Streptorix, for pneumococcal disease; an improved flu vaccine; and vaccine combinations for meningitis.
Glaxo estimates the global market for these vaccines to reach $11 billion to $18 billion in five years. Vaccines accounted for 6 percent of Glaxo's $20 billion revenue last year.
|